A Review on Pharmacological Treatment of Idiopathic Parkinson’s Disease.Bhupendra Shah*
Department of Internal Medicine, BP Koirala Institute of Health Sciences (BPKIHS), Dharan 56700, Nepal
- *Corresponding Author:
- Bhupendra Shah
Assistant Professor, Department of Internal Medicine BP Koirala
Institute of Health Sciences (BPKIHS), Dharan 56700, Nepal
E-mail: [email protected]
Received date: May 28, 2017; Accepted date: June 10, 2017; Published date: June 14, 2017
Citation: Shah B (2017) A Review on Pharmacological Treatment of Idiopathic Parkinson’s Disease. J Neurol Disord 5:347. doi:10.4172/2329-6895.1000347
Copyright: © 2017 Shah B. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Parkinson’s disease is the second most common chronic neurodegenerative disease of central nervous system predominant in elderly people characterised by tremor, akinesia, rigidity and gait disturbances. The annual cost of management of Parkinson’s disease is double than that of control population. Evidence- based management of Parkinson’s disease in developing nation is unmet needs. This article is authors’ endeavour to summarise the facts in different publications on Parkinson’s disease. Electronic databases like MEDLINE/Pub Med, Google Scholar, IMSEAR (Index Medicus for South-East Asia Region) and Scope med were extensively searched with MeSH (Medical Subject Headings) terms “Parkinson’s disease”, “treatment”, and “anti-Parkinson drugs” from the earliest possible date of 1966 to March 2017. Articles in any languages especially those published in recent years were given preference. This review deals mostly with evidence based management of Parkinson’s disease.